Kadcyla HERConnection

Eligibility

Eligible patients must have HER2-positive breast cancer, either as adjuvant treatment for early breast cancer with residual disease after neoadjuvant therapy or for metastatic disease after prior treatment with trastuzumab and a taxane. Selection is based on an FDA-approved test, and patients must have previously received taxane and trastuzumab therapies.